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A 66-year-old black man was admitted to the Ann Arbor Veterans
Administration Hospital with advanced renal failure. He had had type-Il
diabetes mellitus and hypertension for at least 15 years with visual
impairment due to cataracts and diabetic retinopathy. Proteinuria first had
been noted 6 years prior to admission, and one year later the serum
creatinine was 1.0 mg/dl. His serum creatinine level rose to 2.7 and 4.9
mg/dl, respectively, at 11 and 5 months prior to admission. The patient had
been referred to Renal Clinic but missed several appointments. In the
clinic, he refused to discuss plans for end-stage renal disease (ESRD)
therapy and left abruptly on one occasion. Three months prior to
admission he was admitted to another hospital and underwent several
acute dialysis treatments. One month before admission, he developed
nausea, vomiting, diminished appetite, and soon thereafter decreased
urine output. These complaints and the onset of dyspnea prompted his
admission to the VA Hospital. Medications included diltiazem, hydral-
azine, furosemide, and insulin. He smoked one pack of cigarettes daily on
average for the last 40 years.
Physical examination revealed an oriented black man; his blood pres-
sure was 140/80 mm Hg. Chest examination disclosed basilar rales bilaterally
but no perieardial friction rub. He had 1 + anide edema. Vibratory sensation
was decreased in both legs. The chest roentgenogram showed bilateral
pleural effusions and mild eardiomegaly. Abnormal laboratory values
included a BUN of 117 mg/dl; serum creatinine, 14.0 mg/dl; total calcium,
6.0 mg/dl; phosphorus, 10.0 mg/dl; and albumin, 3.1 g/dl; glucose and
electrolytes were in the normal range.
Acute hemodialysis was performed the following day using a subclavian
double-lumen catheter. Long-term chronic dialysis therapy was discussed
with the patient. Members of the renal team expressed reservations about
the patient's ability to comply with and thrive on chronic dialysis. The
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patient was divorced, estranged from his grown children, and out of
contact with his siblings, who lived in other parts of the country.
He did not drive and would not discuss travel arrangements for
receiving dialysis treatments. He did have a friend who lived in the
apartment next door and who assisted with the preparation of meals. The
renal social worker reported that ". . . he wants the treatment since he
knows he will die without it. At the same time it seems quite clear that he
will have much difficulty complying with the requirements necessary to do
well on hemodialysis." Despite these reservations, he was accepted into
the chronic dialysis program and underwent surgical placement of an
arteriovenous fistula.
Initially his course was complicated by multiple failed access procedures
that ultimately required a permanent subclavian catheter (Permacath).
Nonetheless, the patient came in regularly for dialysis and tolerated the
treatments well for approximately one year. Members of the dialysis team
commented that he was doing better than expected. Over the next 6
months, he developed additional problems including symptomatic coro-
nary artery disease, recurrent sepsis, intermittent lapses in mental status,
seizures, and a general failure to thrive. A CT scan documented an old
cerebral infarction. Eventually he was unable to continue living indepen-
dently and was admitted to the VA Extended Care Facility adjacent to the
hospital. During his lucid moments, the patient indicated that he desired
nursing home placement in the hope that his condition would eventually
improve and allow him to return to independent living.
He developed new vascular access problems requiring repeated femoral
vein punctures, and he had an acute ischemic neurologic event with
further decline in his mental status. Subsequent line sepsis and aspiration
pneumonia were treated with antibiotics. As his condition deteriorated, it
became increasingly clear to the medical staff that his progressive prob-
lems were irreversible. The patient was judged to be incompetent to make
medical decisions, although at times he was able to discuss his situation
clearly and indicated a wish to stop dialysis therapy. Attempts to contact
his children remained unsuccessful. Finally, two of his siblings were
contacted; they expressed the opinion that the patient would not want
continued dialysis therapy in the absence of a reasonable chance for
meaningful recovery and independent living. The patient's friend and the
medical staff agreed with this opinion. Therefore, the decision was made
to discontinue dialysis. The patient remained in the hospital for comfort
measures and died peacefully 10 days later in uremic coma.
Discussion
Dn. FRtEDRICH K. PORT (Nephrology Division, and Co-Director,
Kidney Epidemiology and Cost Center, and Professor of Medicine
and Epidemiology, University of Michigan Schools of Medicine and
Public Health, Ann Arbor, Michigan): This patient illustrates some
of the medical and ethical dilemmas presented to physicians as
seriously ill patients approach the terminal stages of chronic renal
failure. This man fits the description by Ifudu et al of "dismal
rehabilitation" in geriatric hemodialysis patients [1}. Although
several of our younger, nondiabetie patients are alive and active
after 15 to 20 years of dialysis therapy, nephrologists now are
faced with an increasingly aging ESRD population. The median
age at onset of renal replacement therapy has reached 62 years
[2]. Today's patient is beyond the median age at 66 years.
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Fig. 1. Life expectancy at age 49 and 59 years
for patients with ESRD, the general population,
and patients with other chronic conditions. (From
Ref. 2.)
Diabetes, this patient's fundamental medical problem, has be-
come the most common condition leading to ESRD, accounting
for 35% to 39% of new patients. Before going into details about
today's patient, I will review the major facts regarding morbidity
and mortality of ESRD patients, primarily using data from the
United States Renal Data System (USRDS) [2] and other studies
of dialysis patients. I will discuss the age-specific life expectancy of
patients with ESRD and will describe co-morbid conditions
present in the average dialysis patient at the start of ESRD and
the influence of those conditions on mortality rates. This back-
ground information will allow us to discuss treatment issues and
view the patient in perspective as well as permit discussion of
some ethical issues raised by this case.
In the United States, we have the benefit of a large and
remarkably complete registry with longitudinal data on approxi-
mately 93% of patients treated for ESRD with dialysis or renal
transplantation [2]. These data are collected by 18 ESRD Net-
works nationwide under contract with the Health Care Financing
Administration (HCFA), which has paid for ESRD care since a
"national health care system" for ESRD was instituted in 1973 [3].
The National Institutes of Health's National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDKD) has funded this
scientific U.S. Renal Data System since 1988 through a contract,
currently with the University of Michigan. The USRDS's tasks go
beyond those of a national registry; supplemental data collections
are available for special research studies (such as the case-mix
severity study), and the data files are shared with researchers
outside of the USRDS Coordinating Center.
Life expectancy in dialysis patients. As with many chronic med-
ical conditions, the life expectancy of patients undergoing therapy
for ESRD is markedly reduced. Quantitatively, this reduction is
greater among younger age groups (Fig. 1); at age 49, life
expectancy is reduced by 23 years, and at age 59 by 17 years.
Without renal replacement therapy, however, these patients
would live only a few weeks before they became uremic and died.
Life expectancy for ESRD patients in this age range is similar to
that for patients diagnosed with a variety of malignancies, includ-
ing carcinoma of the colon. Given the high mortality rate among
ESRD patients, it is worthwhile to explore factors that modify the
present dismal outcome.
Among demographic factors associated with elevated mortality
risk in ESRD, age is the most important, as I just noted. Gender
and race also affect mortality. As in the general population, men
with ESRD have a shorter life expectancy than do women. In
addition, black ESRD patients survive longer than do white
patients [2]. Some of this difference might be related to a higher
transplantation rate in whites [4], which removes more relatively
healthy patients from the white dialysis pool. However, survival
analyses of all patients with ESRD (dialysis and transplant
patients) have shown similar advantages for blacks, particularly
among diabetic patients, even though whites have a higher
transplantation rate [2, 4]. The reasons for this difference remain
unknown. Cause of ESRD is one of the strongest predictors of
mortality. Patients with ESRD due to diabetes have approxi-
mately twice the mortality risk (or rate) as compared with ESRD
patients with glomerulonephritis.
The USRDS has developed treatment-specific mortality tables
for all patients according to 5-year age groups by race and cause
of ESRD (diabetes, hypertension, glomerulonephritis, and other)
[2, 5]. The methodology of using these tables to estimate the
expected death rates for groups of dialysis patients (for example,
by dialysis unit or by region) has been described for all patients
surviving longer than 3 months [5]. These tables have the primary
purpose of allowing comparison of observed deaths with expected
deaths from national data per patient years at risk [5], but they
also can be used to estimate life expectancy for patients according
to their age, race, and disease category. The median expected
survival on dialysis ("life-time") can be calculated for the age,
gender, race, and diagnosis of the patient, under the assumption
that the death rate is constant over time. We use the tables
reported by the USRDS [2] and the following formula:
median expected life time = (In2)/annual death rate.
Today's patient's calculated life expectancy therefore is approx-
imately 2.2 years or 27 months for a 65- to 69-year-old black
diabetic man treated with hemodialysis, according to USRDS data
for 1988—1990 [2]. Limitations to this method [6] include the fact
that the tables describe all patients surviving more than 3 months.
Mortality rates are somewhat higher during the first 3 months of
therapy compared with later intervals [7]. Thus, this method
slightly overestimates the approximate prognosis for new dialysis
patients. Additionally, our patient was sicker than the average 65-
to 69-year-old diabetic male reaching ESRD. To better charac-
terize the patient's condition at the time of presentation, one can
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Table 1. Co-morbid conditions by diabetic status and associated risks in
hemodialysis patients
Co-morbid factor
Frequency of
documentation
Overall Diabetic!
(%) nondiabetic
Relative mortality risk
(versus not present)
Coronary artery disease 40.8 1.38 1.22a
Congestive heart failure 41.1 1.57 1.26a
Active smoker 18.2 0.68 1.26a
Neoplasm history 9.0 0.70 1.42"
Undernourished 13.6 0.71 1.26a
Obesity 20.4 1.75 O.86'
"P < 0.01 by Cox proportional hazards model, which also adjusted for
age, gender, race, diabetes, systolic blood pressure, functional abilities,
serum albumin, creatinine, blood urea nitrogen, and missing indicators
(see Ref. 10).bp <
examine outcome data with consideration of the presence or
absence of co-morbid conditions.
Co-morbid conditions at the start of ESRD. Beyond the basic
factors of age, race, and cause of ESRD, co-morbid conditions
substantially modify the basal mortality risk. Most patients start-
ing ESRD therapy have had renal disease for a variable number of
years and present with anemia due primarily to erythropoietin
deficiency, hypertension, salt and water retention, and some
degree of bone disease related to hyperparathyroidism, deficiency
of vitamin D, and/or aluminum toxicity. Through medical record
abstraction of a representative sample of nearly 5000 of the 66,000
U.S. patients starting ESRD therapy during 1986 and 1987, the
USRDS special study data allow us to describe the fraction of
patients with various co-morbid conditions [8]. Assessment of
co-morbid conditions provides a large analytical benefit, in that it
allows us to consider differences in the case mix of patient groups
when making comparisons among dialysis patients, such as dia-
betics versus nondiabetics, or hemodialysis versus peritoneal
dialysis patients. For example, CAPD patients in the U.S. are on
average 5 years younger than hemodialysis patients [8]. Statistical
adjustments (for example, for age) permit an appropriate com-
parison (adjusted for age mix).
At the onset of ESRD, more than 80% of patients are treated
with hemodialysis [2]. The most common cause of ESRD is
diabetes mellitus; duration of diabetes typically exceeds 10 years
[9]. Since its systemic complications usually are quite pronounced
by the time ESRD is reached, more co-morbid conditions are
expected among patients with diabetic ESRD than among those
with ESRD due to all other causes. Therefore, data on co-morbid
conditions are presented for hemodialysis patients overall and for
those with diabetes compared to those with all other causes for
ESRD. Diabetes was present in 41% of patients but accounted for
only 28% of causes of ESRD in the 1986—1987 sample [8]. The
growth in the number of diabetic ESRD patients has been
markedly faster than that for other causes, so that diabetes led to
ESRD in 34% of new patients in 1990 [2].
Table 1 lists data from this USRDS study [8, 10]. Coronary
artery disease and congestive heart failure each were present in
41% of hemodialysis patients at onset of ESRD, and both were
present more commonly in diabetic than nondiabetic patients. As
additional evidence for documented heart disease, cardiomegaly
and left-ventricular hypertrophy were documented in 38% and
31% of patients, respectively. As expected, these conditions were
more common among diabetic than among nondiabetic patients.
Current smoking was recorded in 18% of patients, and 12% had
chronic obstructive pulmonary disease. Nine percent of patients
had cancer at the onset of ESRD, with myeloma being the most
common neoplastic cause of ESRD [2]. Fourteen percent of
patients were undernourished, as indicated in the medical records,
and 20% were obese, the latter being more common among
diabetics [8]. The average serum albumin level of 3.5 g/dl [101
suggested poor nutritional status in a much larger number of
patients (nearly 50%) than was indicated in the medical records.
When analyzing morbidity and mortality data in any group of
chronic dialysis patients, one must consider the co-morbid condi-
tions I have just briefly reviewed in addition to the basic demo-
graphic data. Patients who have these conditions have a higher
mortality rate than do patients without such problems, but the
magnitude of this excess risk was described only recently [10].
Statistically this risk can be estimated with adjustment for differ-
ences in age, gender, and race using the Cox proportional hazards
model [11]; results of this analysis are shown in Table 1. A relative
risk (RR) of 1.22, as shown for patients with coronary artery
disease, indicates that the mortality risk for these patients on
average is 22% greater than that for patients without coronary
artery disease (as documented in the medical records). If the
overall, average patient mortality was 25% at one year, then the
mortality for those with and without documented coronary artery
disease would be 28% and 23%, respectively, according to
weighted average calculations (0.28/0.23 1.22). Thus, the mag-
nitude of the additional risk imposed by co-morbid conditions
present at the start of dialysis therapy can be determined from this
large national sample.
Several other studies have assessed the trends over time in the
presence of co-morbid conditions [12, 13]. Although some con-
cern exists regarding the validity of these studies because of
improved recording in the medical records over the last 5 to 10
years, there appears to be a definite trend of patients suffering
from more co-morbid conditions at the start of ESRD. Most
studies found such an increase, particularly for the early versus
late 1970s, and a smaller or no increase during the 1980s [12, 13].
This increase in co-morbid conditions at the start of ESRD largely
is related to older patients beginning therapy for ESRD, but the
rise also represents, in part, the recent acceptance of sicker
patients within all age groups. Additionally, there is the so-called
issue of "competing risk." For example, patients who formerly
might have died of atherosclerotic cardiovascular disease now
survive long enough to reach ESRD because of coronary angio-
plasty or bypass procedures.
The magnitude of the risk associated with co-morbid condi-
tions, as estimated from the 1986—1987 national sample of ESRD
patients beginning therapy [10], was greatest for patients with
neoplasms (compared to no neoplasm), elevated by 42% (RR =
1.42). Patients with coronary artery disease or those who smoke
cigarettes each had a 26% higher risk than did patients without
such conditions (adjusting for other conditions). The nutritional
status at the start of ESRD therapy also was a strong predictor of
mortality: undernourished patients had an elevated mortality risk;
so did those with an abnormally low serum albumin level.
Furthermore, a low serum creatinine was predictive of elevated
mortality risk [10, 14]. This apparent paradox, likely explained by
a low production of creatinine in patients with reduced muscle
Relative risk
2.50 NOTE: P values compare to
2.00 -
1.50
IJ<
101
the ref. group (3.5—4.0 gIdl)
<2.5 2.5—3.0 3.0—3.5 3,5—4.0 4.0+
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mass, again suggests that nutritional status at the start of ESRD is
of vital importance. Peculiarly, obesity at the start of ESRD
appeared protective when the data were adjusted for other
factors, including cardiac conditions.
This national study has provided valuable information about
the relative importance of various co-morbid conditions on sub-
sequent survival of chronic dialysis patients. By applying these
documented and statistically significant increased risks from co-
morbid conditions to the average expected mortality figures by
age, gender, race, and cause of ESRD [2, 5], one can better
estimate life expectancy in individual patients. For the patient
presented here, hypoalbuminemia, smoking, and congestive heart
failure were important adverse risk factors. Other studies have
suggested that factors present in today's patient other than those
mentioned are also associated with poor survival. According to
McClellan et al [15], living alone or lack of family support predicts
shorter survival times. Also, we found an inverse correlation
between income and survival [161. Some have suggested that
starting dialysis at an advanced stage of chronic renal failure is
associated with a poor prognosis [17, 18]. The use of a temporary
vascular access similarly can cause poorer outcomes. Thus, con-
sidering all these adverse factors, the prognosis for the patient we
are discussing would be further limited for a life expectancy
shorter than 27 months.
How can therapy improve survival? Using data from the Michi-
gan Kidney Registry, we recently showed in an appropriately
controlled group of patients who were suitable transplant candi-
dates that cadaveric renal transplantation was markedly superior
to dialysis in extending patient survival [19]. Cumulatively, the
excess mortality during the first month after transplantation was
balanced by a decrease in mortality by 10 months after transplan-
tation. Unfortunately, the growing need for cadaveric organs far
exceeds the supply in the U.S.; the waiting time is ever increasing.
Living-related donor transplantation has been shown to give far
superior survival results than cadaveric transplantation, and I
believe that it deserves greater emphasis in the management of
ESRD in the U.S. [2, 20].
Prospective trials in dialysis have been limited. The National
Cooperative Dialysis Study (NCDS), carried out more than 10
years ago, grouped patients into four treatment protocols of short
versus long treatment times and high versus low average BUN
concentrations. The main findings of this study were that the dose
of dialysis predicted morbid events and that the best measure of
the dialysis dose was the dialyzer clearance (Kd) per urea
distribution volume (V), times the hours of dialysis (t) [21, 22]. To
estimate the effect on the patient, the total dialysis dose has to
factor in the residual renal function (Kr). Unfortunately, these
NCDS data do not represent patients of the 1990s because the
study excluded diabetics and patients treated with bicarbonate
dialysate, which now account for 35% and 85% respectively of
new ESRD patients.
Recent studies on this topic are cross-sectional observational
studies and assess the mortality risk by dose of dialysis. The
USRDS case mix studies [23, 24] found a strong correlation
between KtIV (a measure of the delivered dose) and mortality
risk. In the case mix adequacy study [24], patients who had been
on hemodialysis for less than one year were excluded from
analysis in order to minimize the role of unmeasured residual
renal function, which typically diminishes during the first year of
hemodialysis. Similarly, Owen et al reported a strong correlation
Serum albumin, g/dl
Fig. 2. Correlation of mortality risk (Cox) by serum albumin concentration
in new hemodialysis (2897) and CAPD (666) patients within 6 weeks of
starting ESRD therapy. (From Ref. 23.)
between urea reduction ratio (equivalent to Kt/V) and mortality
risk [25]. These epidemiologic studies have not tested the effect of
therapeutic maneuvers but nevertheless suggest that a higher
dialysis dose would be beneficial to hemodialysis patients. Others
have reported similar findings with much smaller sample sizes
[13]. The potential benefit of longer treatment times [26, 27] in
addition to Kt/V deserves further study and is currently being
investigated by the USRDS.
Greater attention to nutritional therapy also might benefit the
dialysis patient [28, 29]. As Figure 2 shows, a strong inverse
correlation exists between serum albumin and mortality risk for
both hemodialysis and CAPD patients [14, 23]. Other studies
reporting an even steeper correlation might be biased because
they use each patient's mean albumin level that includes serum
albumin levels just prior to death. Multivariate outcome studies
must not predict future mortality by including information gath-
ered after the study started. Since a low albumin can be an
outcome, the serum albumin level averaged over the time of study
rather than at baseline "overpredicts" the association with mor-
tality. In the historical prospective study of the USRDS, hypoalbu-
minemia and malnutrition were independent predictors of mor-
tality [10, 23]. Although this cross-sectional observation does not
prove that nutritional intervention alters outcomes, it suggests
that nutritional intervention would improve outcomes in under-
nourished patients.
Whereas dietary protein intake has been studied from urea
generation, few studies have addressed the role of adequate
caloric intake [30]. Most studies on caloric intake have been
limited to a handful of patients because of methodologic difficul-
ties. Good evidence suggests that restricting dietary protein to less
than 1 g/kg body weight is potentially harmful to dialysis patients
[31] and that attention to caloric intake is important for generally
undernourished patients, even though the evidence is stronger for
protein malnutrition (as manifested by hypoalbuminemia). The
statistically significant inverse correlation between serum albumin
at the start of ESRD therapy and mortality risk suggests that
attention to nutrition even before the onset of ESRD is important.
Some investigators have argued that early initiation of dialysis
would benefit patients because the anorexia due to early uremia
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may be avoided [17, 18]. Such a benefit from early dialysis has not
been adequately proved in ESRD.
The use of high-flux hemodialyzers also might improve patient
outcomes. Held et al have shown a benefit in a recent national
study [321, and others have suggested improved outcomes from
high-flux dialyzers when compared with conventional dialyzers
[33]. This observation, if confirmed, might be due to a relatively
greater clearance by high-flux dialysis of larger molecules (oh-
gopeptides to "middle molecules") compared with small mole-
cules (urea). Alternatively, the greater biocompatibility of high-
flux membranes compared with cellulosic membranes might
account for these observations. Further studies are needed to
explore these issues.
Overall differences in patient care may explain in part the wide
variation in adjusted mortality rates among dialysis centers [34,
35]. Differences in transplantation rates might also contribute to
this variation [35]. Dialysis unit staffing might play a role [34] and
other factors might contribute, such as nephrologist training [361
and perhaps frequency of patient contact. Attention of health care
professionals to control of hypertension and hyperlipidemia and
to issues such as continuous quality improvement [37], family
support [15], and rehabilitation are likely important as well. This
partial list of a variety of factors that affect overall outcome
indicates a clear need for better studies to explain the large
"center effect" [38].
Recent studies have shown an elevated mortality risk associated
with certain types of dialyzer reuse compared with no reuse [32].
The correlation between dialyzer reuse and specific dialysis center
standardized mortality rates is statistically strong. The investiga-
tors have pointed out, however, that it might not be the specific
reuse agent(s) but rather the actual method utilized and followed
in free-standing facilities. Thus, either avoidance of reuse or strict
adherence to recommended reuse practices [39] might result in a
lower mortality risk.
Several other factors that potentially affect patient outcome
deserve consideration, although they have been insufficiently
studied in ESRD patients. These include control of hypertension,
treatment of hyperlipidemia, occupational rehabilitation, and
others.
Morbid events, complications. The frequency of morbid events
has been studied in single centers, but these findings are not
representative of the country as a whole, given the variability in
outcomes by center. The frequency of hospitalizations, a reason-
able proxy for morbid events, has been reported by the USRDS
[7] with more detailed studies among dialysis patients. Diabetic
ESRD patients can expect to be hospitalized more than twice
yearly; nondiabetic patients on average have 1.5 admissions per
patient year [40]. The corresponding numbers of hospital days
average 24 and 15 per patient year, respectively. Hospitalizations
are more frequent among whites than blacks and increase in both
groups, as anticipated, with age. Vascular access problems and
cardiovascular complications are the most common reasons for
hospital admissions [2]. Both these complications were observed
in today's patient. Overall, hospitalization rates for 1988 through
1990 appear to be higher among patients treated by peritoneal
dialysis than in those having hemodialysis [40]. This finding might
be related to hospitalizations due to peritonitis, although the
frequency of this complication has been reduced with newer
connection techniques [41]. Studies of mortality risk by treatment
modality have shown similar outcomes for incident CAPD and
hemodialysis patients among nondiabetic patients, and higher
mortality rates among older diabetic patients treated with CAPD
versus hemodialysis [42]. The role of the actually delivered dialysis
dose (as distinct from the prescribed dose) for these patient
groups has not been considered in these studies, and subtle
differences in patient selection might further influence these
results. The better survival reported for young diabetic CAPD
patients versus hemodialysis patients [43] is in part explained by
patient selection [42].
Medical complications developing in dialysis patients can lead
to death and deserve attention. Our experience with cerebrovas-
cular accidents (CVAs) can be looked at from the perspective of
national data on causes of death of dialysis patients. Overall, the
death rates due to CVA are 1.4/100 dialysis patient years and 2.0
for those over age 65 years; CVAS account for more than 5% of
deaths [21. There likely is underreporting of serious complications
such as CVA, because withdrawal from dialysis (no matter what
the precipitating cause) has competed as a primary cause of death
on the ESRD Death Notification Form until the form's revision in
1991. I will address the issue of withdrawal from dialysis following
serious complications in a moment. The death rate from CVAs
fell during the 1980s [44]. I suspect that improved blood pressure
control owing to better antihypertensive agents contributed to this
declining death rate. The lack of a decline in cardiac deaths (due
to myocardial infarction, sudden death, congestive heart failure,
etc.) might be related to less-specific reporting for cardiac causes.
Withdrawal from dialysis has accounted for approximately 10% of
all deaths reported and for a greater fraction among older age
groups [2]. Let us now turn to issues related to withdrawal from
therapy in today's patient.
Ethical issues. Today's case presentation illustrated great am-
bivalence, both on the part of the patient and of the dialysis unit
staff, regarding the initiation of dialysis. In view of the patient's
poor general health, lack of family support, and poor long-term
prognosis, we all questioned the potential benefit of treating his
ESRD [45]. Of course the patient must be involved in such a
decision. In this case, the patient changed his mind from refusing
dialysis to wanting dialysis. Patients should receive frank informa-
tion regarding the benefits, risks, physical limitations, adaptations,
and prognosis with and without dialysis therapy early in the course
of ESRD (as he apparently did). These discussions must take
place during the early phase of progressive, chronic renal failure,
as the onset of uremic encephalopathy prevents competent deci-
sion-making thereafter.
This patient changed his earlier decision (refusing initiation of
dialysis). We should consider such a decision as potentially
reversible as long as patients are deemed competent and can
communicate a change of mind. Several opinion polls of neph-
rologists have tried to address the ethical issues of not starting
dialysis therapy versus discontinuing therapy. Although nephrolo-
gists tend to view stopping dialysis as more difficult than not
starting [46], most medical ethicists agree that these two options
are philosophically similar and that physicians' preferences for not
starting rather than stopping dialysis has no foundation in ethics.
Quality of life is a subjective measure. Physicians must not
project their personal opinions regarding quality of life onto their
patients. Today's patient was later noted to be "doing better than
expected." In a striking example of patients' perceptions of quality
of life, Westlie et at [47] reported that elderly dialysis patients in
nursing homes on average judge their quality of life to be superior
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to that of their peers in the nursing home who do not have renal
failure.
Are physicians justified in bringing up the question of the
circumstances under which their patients would consider discon-
tinuing dialysis therapy? In recent years some patients told my
dialysis team that they actually were relieved when we raised this
issue before major complications developed. There are advan-
tages to advanced directives [48]. Such discussions also apply to
patients who would be excellent candidates for dialysis but who
refused initiation of dialysis. Such patients may benefit from a trial
of a few weeks therapy, with the mutual understanding that they
have not lost control but can request discontinuation of dialysis.
Demographic factors associated with discontinuation of dialysis
include advanced age, white race, diabetes as cause of ESRD [49],
and CAPD therapy [50]. The decision, however, frequently fol-
lows a major medical illness such as a stroke [51]. A general
downhill course, or "failure to thrive," is another common
contributing factor [52]. One must be cautious that this course is
not a consequence of an inadequate dose of dialysis, which may be
insidious due to a gradual loss of residual renal function or
deterioration of the vascular access. The elder Dr. George
Schreiner has recommended a course of intense dialysis with
liberal protein and high caloric nutrition before considering a
patient's wish to stop dialysis; one of his patients told him not to
listen to his request when his "uremia is speaking" (personal
communication). From our own experience, I believe that input
into the decision-making process from several health care profes-
sionals, including social workers, nurses, and dietitians, in a
formal meeting is helpful. It provides some safeguards against
improper decisions without removing the burden of responsibility
from the nephrologist. Given the ever-growing abilities of modern
technology to keep patients alive, it becomes increasingly impor-
tant to deal with these difficult ethical problems [53].
Summaty. Today's patient demonstrates many of the difficulties
in dealing with geriatric and diabetic ESRD patients. Co-morbid
conditions, including impaired nutritional status, are frequently
present at the start of ESRD and predict a significantly elevated
risk of mortality. The morbidity and mortality observed among
dialysis patients is high, even compared with many types of cancer
such as cancer of the colon. Treatment factors that may improve
outcomes include renal transplantation and a relatively high dose
of dialysis (Kt/V over 1.2—1.4), greater attention to dietary intake,
delivery of high-quality care, and possibly early start of dialytic
therapy and use of biocompatible/high-flux dialyzers.
The ethical issues for this patient can be summarized as follows:
Dialysis was started when he reversed his earlier decision and
desired therapy. He fared better than expected until complica-
tions developed including CVA, sepsis, and general failure to
thrive. After discussion among his medical team, the patient, and
his family, it appeared appropriate to follow the patient's request
to discontinue dialysis. As Dr. Jerome Kassirer eloquently stated,
"The sick suffer enough; we must avoid adding insult to injury by
denying them a proper role in determining their future" [54].
The area of ethics in dialysis demands further study. Issues such
as initiation versus discontinuation of dialysis are complex and
require consideration by patients and health care professionals. I
suspect that dialysis units and nephrologists who have strict entry
criteria for initiation of dialysis also tend to be reluctant to
consider stopping dialysis, whereas those with more liberal accep-
tance criteria also are more likely to consider discontinuation of
dialysis. My preference [55] is to offer dialysis with little restriction
but with the understanding that it may be discontinued when the
course shows an irreversible downhill trend despite maximal
therapy.
Questions and answers
DR. JOHN T. HARRINGTON (Chairman, Department of Medicine,
Newton-Wellesley Hospital Newton, Massachusetts): If you were
suddenly made the Czar of Dialysis in the United States, how
would you encourage and enforce provision of high-quality dial-
ysis to every patient, every dialysis?
DR. PORT: That's a difficult question, and I'm glad I'm not the
czar. The hidden issues here are that there is a cost to providing
a high-quality and high dose of dialysis. It may not be a coinci-
dence that the duration of dialysis, and likely the dose of dialysis,
was reduced during the 1980s, when dialysis reimbursement also
was being reduced. Medicare reimbursement for dialysis was
decreased by 50% (inflation-adjusted dollars) during the 1980s,
and the delivered dose has had some correlation with the reim-
bursement level. Philip Held has shown that the staffing for
dialysis was reduced more in regions that experienced a greater
reduction in the reimbursement [34].
How could you increase the delivered dialysis dose without
increasing the cost? You can, in fact, increase the dose of dialysis
quite markedly at a relatively small cost or almost nonexistent
added cost, particularly if you reuse dialyzers. We have recently
shown that there is a potential risk associated with certain dialyzer
reuse [32]; however, the risk of low-dose dialysis might be even
greater. If dialyzer reuse is practiced correctly, it might be safe.
With reuse of dialyzers, you can afford to use a highly efficient and
more costly dialyzer. Given that the average number of times a
dialyzer is reused is 13 times in this country [32], a dialyzer costing
$10 for a single use can easily be replaced with one costing $30 for
the 13 uses. If you reuse dialyzers already, then replacing a $15
dialyzer with a larger, $30 dialyzer would cost only $1.15 per
dialysis. Additionally, you can increase the blood flow rate
through the dialyzer to increase the efficiency of dialysis. In the
United States, the median blood flow rate was 250 mI/mm in
1986/1987 [56]. The blood flow can be increased in many patients
to 300—500 ml/minute without placing much additional stress on
the patient. Thus, at a similar cost, a bigger dialyzer and higher
blood flow rates can be employed. The third option—giving
longer dialysis treatments—is likely to be quite costly. We need to
first document that treatment time (T) is an important predictor
of survival beyond Kt/V, before we need to recommend a higher
T.
DR. HARRINGTON: More specifically, how would you ensure that
all those methodologies you just referred to would, in fact, be
utilized in the typical dialysis unit?
DR. PORT: There has been a system in place since 1990. The
ESRD Networks have been charged by HCFA to collect informa-
tion on samples of patients regarding deviations from some
minimum criteria for urea reduction or Kt/V [57].
DR. Ricitiw LAFAYETTE (Division of Nephrology, New England
Medical Center, Boston, Massachusetts): Dialysis patients clearly
have a dreadful life expectancy. However, one is always struck by
the fact that patients without significant co-morbidity sometimes
live for long periods on dialysis. Thus, one wonders whether the
anephric condition itself or the high co-morbidity of the dialysis
population leads to the dramatic decrease in patient survival. You
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pointed out a 41% prevalence of coronary heart disease, a 41%
prevalence of heart failure, 18% smokers, and the high rates of
hypertension and diabetes. If one screened for the absence of all
these factors, would the dialysis treatment or lack of renal
function itself result in decreased life expectancy?
DR. PORT: In our own dialysis unit, we have several nondiabetic
patients who have undergone 15 to 20 years on dialysis and who
are doing quite well. Thus, we know that dialysis can be an
adequate renal replacement therapy. The issue of dialysis dose is
important particularly after the patient loses residual renal func-
tion. We must remember that dialysis provides only partial renal
replacement with an average clearance for creatinine or urea of
less than 15 ml/min. Patients who have a residual renal function of
more than 3 or 4 ml/min are not likely to receive inadequate
dialysis.
DR. ROBERT S. BROWN (Division of Nephrology, Beth Israel
Hospital, Boston): You pointed out that high-flux dialysis might
offer a better prognosis than routine dialysis even though it is
usually of shorter duration. However, high-flux dialyzers are
generally made with more biocompatible membranes than the
average low-flux or normal-flux dialyzer. Do you have any data on
survival based on the biocompatibility of the dialysis membranes
to which we are exposing our patients?
DR. PORT: At USRDS we are pursuing this very important
question. I made the point earlier that the roles of high-flux and
more biocompatible dialyzers are difficult to differentiate. There is
evidence that phagocytic function is less impaired and that
infection risk is lower if you use biocompatible membranes than if
you use non-biocompatible membranes [58]. High-flux dialyzers
virtually always have biocompatible membranes. Your question
raises an important point: We do not know whether biocompat-
ibility or clearance of middle molecules is important.
DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): These are remarkable data that you've shown us
regarding the correlation of Kt/V and survival. Are these data
adjusted for all the baseline co-variates that you have shown to be
important?
DR. PORT: Yes, they were adjusted for age, gender, race, cause
of ESRD, several co-morbid conditions, and laboratory values
such as BUN and serum albumin. This is an adjusted analysis
using the Cox proportional hazards model.
DR. LEvEY: Are these analyses also adjusted for weight? On
average, smaller patients receive a higher dose of dialysis.
DR. PORT: Yes, smaller patients (by weight) and females tend to
receive a relatively high KtIV. In a sensitivity analysis, we also
adjusted for weight and found the same significant correlation
between Kt/V and mortality risk.
DR. THEODORE I. STEINMAN (Division of Nephrology, Beth Israel
Hospital): The issue of nutrition obviously becomes paramount in
considering the greater death rates in whites than blacks. Have
you factored in the serum albumin in terms of a potential
mortality predictor for whites versus blacks? Do white patients
have a lower serum albumin than do blacks? If so, could the
difference explain the variation in death rates?
DR. PORT: We have compared serum albumin levels among
various patient groups and found only minute differences [591.
The observation of better survival for blacks was present among
diabetic patients even when we adjusted for albumin level and
co-morbid conditions [42].
DR. SmINw: Serum albumin as a predictor of mortality is less
pronounced in the peritoneal dialysis population than in the
hemodialysis population, especially in the albumin range of 3.0 to
3.5 g/dl. Also, the group with an albumin level above 4.0 g/dl had
a mortality rate close to the reference range of 3.5—4.0 gldl. There
was no further decline in mortality at the higher albumin level in
contrast to the hemodialysis population. Do you have any com-
ments on the difference between hemodialysis and peritoneal
dialysis at the higher albumin values?
DR. PORT: We would have to have a larger sample size to
answer this question. The observation you described is too
preliminary given the small sample size for CAPD. For the main
analysis, a continuous variable for serum albumin was used, which
showed similar results for CAPD as for hemodialysis patients.
DR. KLEMENS MEYER (Division of Nephrology, New England
Medical Center): You have shown us strong retrospective data
about the inverse relationship between Kt/V and mortality. Are
the data so strong that a prospective study is really necessary? Is
it a good way to spend the country's money? The protocol for the
Morbidity and Mortality in Hemodialysis trial proposes to com-
pare treatments that deliver double-pool KtIV of 0.95 to treat-
ments that deliver double-pool Kt/V of 1.4. Is this ethically
defensible? Do we need to do the study, or should we go ahead
and dialyze our patients more?
DR. PORT: Your question has several parts. I agree that it's
ethically not supportable to reduce the dose of dialysis. It seems
that the study Kt/V of 0.95 by double-pool analysis corresponds to
a single-pool Kt/V of about 1.2. This level is likely near the
average in the collaborating research centers. Thus, there won't be
much if any reduction in Kt/V for the lower-dose group. Increas-
ing the dose is certainly justifiable. Epidemiology gives answers
that are often preliminary assessments. Frequently such studies
are hypothesis generating; they tell us about issues that need to be
pursued. The way post-dialysis BUN is measured in a non-
research setting is an inaccurate parameter for estimating the
delivered KtIV. Despite this concern we found a strong correla-
tion. The new study will teach us about the proper measurement
and interpretation of post-dialysis BUN and about the more
precise correlation of Kt/V with morbidity and mortality with a
better measure for Kt/V [60]. The correlation might be steeper
than what we described.
DR. Nicoios E. MAmAs (Chief Division of Nephrology, New
England Medical Center): You mentioned that about 14% of the
patients are undernourished at the start of ESRD and that
undernourishment increases mortality by 26%. Could you please
tell us what criteria were used to define undernourishment in that
study? Also, did the analysis adjust for associated clinical condi-
tions?
DR. PORT: Your second question is easy to answer: yes, the
co-morbid conditions were taken into account. This was not a
prospective research study but a random sample of patients from
across the country. Undernourished was labeled simply according
to findings noted in the medical records. I would assume that
when the record reads "undernourished," the patient is severely
undernourished. We don't have a clean and rigorous prospective
study of undernourishment, however.
DR. LEVEY: The serum albumin is a very strong predictor, as
you pointed you, yet it is often simplistically equated with
nutritional status. In reality it might reflect other factors. For
example, a low pre-dialysis serum albumin level might reflect
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overhydration. What can the USRDS do to ferret out the meaning
of a low serum albumin?
DR. PORT: We have adjusted the albumin for congestive heart
failure—that's one point. The albumin was recorded, if it was
measured, between 2 weeks before and as long as 6 weeks after
the start of ESRD therapy using a mean value for multiple
readings during this interval. I agree that it might be diluted from
volume overload, particulary if measured early. I believe that
variabilities of similar magnitude exist due to the laboratoiy
method that is used. Blagg et al have shown a 0.5 g!dl difference
in serum albumin by the bromcresol purple versus the bromcresol
green method [61]. If we knew the method used and could correct
for it, perhaps we could find an even stronger correlation than that
described here. To deal with the issue of fluid overload, a
post-dialysis serum albumin level might be a better predictor.
Others have pointed out that a pre-albumin level is an even
stronger indicator of nutritional status, but as you know the
medical records rarely give you a pre-albumin measure.
DR. JULIA R. NEURINGER (Division of Nephrology, New England
Medical Center, Boston, Massachusetts): Do you routinely perform
subgroup analyses on the data? For example, you said that
diabetes in the ESRD population is really two diseases. Have you
found any significant survival differences between the insulin-
dependent and non-insulin-dependent patients? Also, do patients
with polycystic kidney disease or tubulointerstitial disease have
longer survival than do patients with other causes of ESRD?
DR. PORT: We have looked at patients receiving insulin among
those with diabetes as the cause of ESRD. Patients receiving
insulin tend to have a slightly higher mortality risk than do other
diabetic patients. The data in the USRDS unfortunately are weak
regarding the type of diabetes. When patients are reported to
have type-I diabetes (IDDM), it seems that the majority of them
in fact have insulin-requiring, but not necessarily insulin-depen-
dent, diabetes. We have learned this from our earlier studies
showing that beyond age 50 or 55 years at ESRD onset, only a vesy
small fraction of patients in Michigan had type-I diabetes [62]. By
contrast, in the USRDS, one-third of new patients over age 60 are
labeled as having IDDM [7]; this number suggests a serious
problem of misclassification for diabetes type. In a Michigan
Kidney Registry study of ESRD by diabetes type, we found that
the survival advantage of black patients over white patients was
similar for both types of diabetes [63]. Patients with polycystic
kidney disease have a better survival rate than do most other
groups [52], and yes, we do perform further subanalysis, as shown
in the 1994 USRDS Annual Data Report [52].
DR. M.DIAs: Could you please contrast some of the findings of
the USRDS data base with those reported by foreign ESRD
registries?
DR. PoRT: We have reported comparative survival rates for the
United States versus Europe and Japan [56]. For all age groups
over 30 years, both diabetic and non-diabetic patients with ESRD
had a lower 5-year survival in the United States than in Europe or
Japan. A potential problem exists in comparisons of different
registries: the quality of the data in different registries is not well
documented. The USRDS receives information about deaths
from the HCFA Death Notification Forms; however, only 90% of
deaths are reported by this form [2]. Thus the USRDS death rate
would be markedly lower because 10% of deaths would have been
missed. The USRDS and HCFA use Social Security information,
which is more complete than that in Europe or Japan because a
death benefit is paid by the U.S. government. Thus, the USRDS
captures an additional 10% of deaths. Other registries just use
notification from ESRD facilities, and likely have an undercount
of deaths. This would result in a much better apparent outcome.
Maybe the completeness of the USRDS data gives the false
impression of a relatively poor survival outcome. This interna-
tional study [56] led us to look at the dose of dialysis in the
European registry versus that in the U.S. The prescribed dose of
dialysis, in our estimation, might be as much as 30% higher in
Europe than in the U.S. [64] and there is likely a difference in the
outcome according to the dose of dialysis. In Japan, the reim-
bursement is calculated by the hour of dialysis. Perhaps this
method of reimbursement is the reason for the relatively long
duration of dialysis treatments in Japan. Thus, Japanese patients
likely receive a larger dose of dialysis, which might in part explain
why their survival rates are better than those for the United
States. International comparisons are useful in pointing out some
potential differences, particularly regarding modality selection[65], but they have weaknesses in that the data sources are
substantially different.
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